AP Biosciences Inc
6945
Rank in Stocks
#14177
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company... AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
Share Price
$3.49
Last synced: 2026-11-10
Market Cap
$340.43M
Change (1 day)
2.23%
Change (1 year)
-5.10%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade AP Biosciences Inc (6945)
Category
Healthcare
Operating Margin for AP Biosciences Inc (6945)
Operating Margin as of November 2026 TTM: 0.00%
According to AP Biosciences Inc's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for AP Biosciences Inc from 2020 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -1,077.35% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -2,670.06% | -8,257.84% |
| 2020 | 32.73% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about AP Biosciences Inc's operating margin
What was AP Biosciences Inc's operating margin in 2025?
In 2025, AP Biosciences Inc's operating margin was 0.00%, compared with 0.00% in 2024.
How has AP Biosciences Inc's operating margin changed since 2020?
From 2020 to 2025, AP Biosciences Inc's operating margin was highest in 2020 (32.73%) and lowest in 2021 (-2,670.06%).
How does AP Biosciences Inc's operating margin compare with similar companies?
AP Biosciences Inc's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.